Pounds 1.1m Boost for Research Won by Gene Therapy Firm
A high-tech Staffordshire firm at the cutting edge of the growing gene therapy replacement market has received a pounds 1.1 million funding boost.
Stoke-on-Trent-based NanoTherics, a spin out firm from Keele University, develops more efficient ways to improve research into genetic disease disorders.
It has received the funding from a group of investors, including pounds 600,000 from Catapult Venture Managers' Advantage Enterprise and Innovation Fund and pounds 200,000 from the Mercia Technology Seed Fund, with the remainder coming from private investors.
NanoTherics chief executive Dr Linda Cammish said the company's work was in an area that could have a huge impact on human health.
"Gene therapy, including stem cell therapy for example, has the potential to dramatically change the treatment of human disease," she said.
"This investment comes at a key point in the company growth strategy and will enable us to place additional resources into the commercialism of our products.
"In the future, such therapies derived from research which can benefit from use of NanoTherics products could be used to treat a wide variety of geneticbased diseases and disorders including cancer, Parkinson's disease, spinal cord injuries, multiple sclerosis, and muscle damage, amongst a number of other impairments and conditions. …